These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36678756)

  • 1. Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment.
    Kerr CP; Grudzinski JJ; Nguyen TP; Hernandez R; Weichert JP; Morris ZS
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
    Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
    Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumor efficacy of
    Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
    Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
    Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
    Bellavia MC; Patel RB; Anderson CJ
    J Nucl Med; 2022 Nov; 63(11):1636-1641. PubMed ID: 36215570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrin α
    Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
    Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
    Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
    Kleinendorst SC; Oosterwijk E; Bussink J; Westdorp H; Konijnenberg MW; Heskamp S
    Clin Cancer Res; 2022 Sep; 28(17):3652-3657. PubMed ID: 35471557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction to radiobiology of targeted radionuclide therapy.
    Pouget JP; Lozza C; Deshayes E; Boudousq V; Navarro-Teulon I
    Front Med (Lausanne); 2015; 2():12. PubMed ID: 25853132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.
    Damiana TST; Dalm SU
    Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34067215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
    Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy.
    Adhikarla V; Awuah D; Caserta E; Minnix M; Kuznetsov M; Krishnan A; Wong JYC; Shively JE; Wang X; Pichiorri F; Rockne RC
    Front Immunol; 2024; 15():1358478. PubMed ID: 38698840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination Strategies to Improve Targeted Radionuclide Therapy.
    Chan TG; O'Neill E; Habjan C; Cornelissen B
    J Nucl Med; 2020 Nov; 61(11):1544-1552. PubMed ID: 33037092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted α-Therapy Using
    Ertveldt T; Krasniqi A; Ceuppens H; Puttemans J; Dekempeneer Y; Jonghe K; Mey W; Lecocq Q; Vlaeminck Y; Awad RM; Goyvaerts C; Veirman K; Morgenstern A; Bruchertseifer F; Keyaerts M; Devoogdt N; D'Huyvetter M; Breckpot K
    J Nucl Med; 2023 May; 64(5):751-758. PubMed ID: 37055223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
    Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
    Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
    Ruigrok EAM; Verkaik NS; de Blois E; de Ridder C; Stuurman D; Roobol SJ; Van Gent DC; de Jong M; Van Weerden WM; Nonnekens J
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT).
    Grzmil M; Boersema P; Sharma A; Blanc A; Imobersteg S; Pruschy M; Picotti P; Schibli R; Behe M
    J Hematol Oncol; 2022 Aug; 15(1):123. PubMed ID: 36045419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.